Lipella Pharmaceuticals, Inc. · OTC:LIPO
Lipella Pharmaceuticals — Investor Presentation (January 2023)
23 slides from Lipella Pharmaceuticals's investor presentation, January 2023
Slide 1: Liposomal Drug Delivery to Mucosal Surfaces
Liposomal Drug Delivery to Mucosal Surfaces 1
Slide 2: Disclaimers
Disclaimers The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (together with its subsidiaries, “Lipella” the “Company,” “we,” “us,” or “our”) during this informational meeting. We request that you keep any information we provide
Slide 3: Executive Summary
Executive Summary Emerging, clinical-stage, proprietary 505(b)(2) opportunity Overview of Opportunity Drug-Delivery Focused Biotech 505(b)(2) Optimized for LP-10 is a phase-2a, 505(b)(2) drug candidate for epithelial tissues Patented liposomal hemorrhagic cystitis Lower systemic drug local drug deli
Slide 4: Company History
Company History Born out of an NIH funded research collaboration on liposomal drug delivery to become a clinical-stage pharmaceutical company with a growing pipeline. 2005 2008 2012 2020 2021 2022 Jonathan Kaufman Michael Chancellor LP-10 FDA Orphan Platform patent Doug Johnston 8 clinical co-founds
Slide 5: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss
Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss Hemorrhagic cystitis is a serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy. Millions of patients 20% of such An increasing US Years after Hemorrhagic are increasingly patients receive popula
Slide 6: Cancer Survivorship & Hemorrhagic Cystitis
Cancer Survivorship & Hemorrhagic Cystitis Expected annual revenue per patient is $20,000 Market penetration of 60,000 patients (45%) yields $1.2 billion annual revenue The current phase-2a is focused on radiation cystitis. LP-10 is also expected to address hemorrhagic cystitis from chemotherapy. Pr
Slide 7: LP-10: Technology, Indication and Economics for Hemorrhagic Cystitis
LP-10 for Hemorrhagic Cystitis LP-10 : Liposomal tacrolimus for hemorrhagic cystitis, phase-2a drug candidate Technology Platform Liposomal Patent protection technology 505(b)(2) focus tacrolimus through 2034 Indication Hemorrhagic Serious No adequate cystitis condition therapy High morbidity Econom
Slide 8: Stops Bleeding via Two Modes of Action
LP-10 Stops Bleeding via Two Modes of Action Tacrolimus’ molecular mechanism includes calmodulin mediated t-cell inhibition Reduce capillary Inhibits cytokine Increased efficacy blood flow cascade probability • LP-10 is a potent • LP-10 is a potent Well-known vasoconstrictor anti-inflammatory pharma
Slide 9: Product Form
LP-10 Product Form Liposomal tacrolimus treatment for hemorrhagic cystitis Sterile Easy powder to deliver Low COGS In-house CMC 9
Slide 10: LP-10 Expected Regulatory Pathway
LP-10 Expected Regulatory Pathway Given the severity of the disease and the lack of adequate treatment, we anticipate that LP-10 will be a good candidate for multiple accelerated regulatory pathways. LP-10 Regulatory Pathway 505(b)(2) Reformulated Fast-track Breakthrough approval generic with design
Slide 11: LP-10: an Outstanding Drug Candidate
LP-10: an Outstanding Drug Candidate Multiple reasons increase LP-10 probability of success Potential 505(b)(2) $1.2 billion Well known Ongoing pathway revenue mechanism clinical of action evidence Accelerated FDA path- Pre-clinical Orphan US FDA IND way efficacy Designation approval candidate 11
Slide 12: LP-10 Phase 2a Trial Design Summary
LP-10 Phase 2a Trial Design Summary Multi-center, dose-ranging study Details Refractory moderate-to-severe hemorrhagic Indication cystitis (HC) Dose ranging study to evaluate safety, Protocol design tolerability, and efficacy of LP-10 Subjects 12 Male and Female subjects from 5 sites Up to 2 instill
Slide 13: Phase 2a Trial Design Summary: Inclusion and Exclusion Criteria
LP-10 Phase 2a Trial Design Summary Key inclusion criteria: Key Exclusion criteria: 1. Males and females, at least 18 years 1. Patients taking immunosuppressive 2. History of sterile moderate to severe HC therapy (Grades 2-4) for at least 3 months with at 2. History of interstitial cystitis/bladder
Slide 14: Phase 2a Trial: Recruitment Sites and Subject Disposition
LP-10 Phase 2a Trial Design Summary Recruitment sites and subject disposition Patient Disposition Number Comments Screened, n 15 14 male, 1 female Enrolled, n 13 13 male 2 instillations (n=10) Number of instillations 23 1 instillation (n=3) Discontinued, % 0 Withdrew consent, % 0 Lack of compliance,
Slide 15: Phase 2a Trial: Patient Demographics
LP-10 Phase 2a Trial Design Summary Patient Demographics Mean Comment Age, years 67 Range 25-89 Race White 9 Non-White 4 Radiation induced HC 11 Chemotherapy induced HC 2 Cancer Prostate cancer 9 Bladder cancer 2 Lymphoma 2 Duration of HC years 4 Range 1 -14 years medication, HBO, catheters, Prior H
Slide 16: LP-10 Safety
LP-10 Safety Adverse events (AE) Number Comment Product related significant adverse events 0 Subject discontinuations 0 Number of subjects with adverse events 5/13 11 AEs reported in 5 subjects 2 mg: 3 AEs in 2 subjects 4 mg: 2 AEs in 1 subject 8 mg: 6 AEs in 2 subjects Bladder spasm, urinary urgenc
Slide 17: Pharmacokinetics and Safety
LP-10 Pharmacokinetics and Safety Local delivery of tacrolimus limits systemic distribution • < 1.5 ng/ml considered undetectable • All Levels were within the safe range, < 15 ng/ml • The 2 mg and 4 mg doses peaked at 1 hour and cleared by 4 hours in all subjects 17
Slide 18: Responder Analysis
LP-10 Responder Analysis Evaluating cystoscopy, hematuria, and symptoms (NR=“no response”, PR=“partial response”, CR=“complete response”) (normalized rank, 0 to 9) cystoscopy hematuria • Efficacy CR in all subjects symptoms improvement 9 reported by principal normalized response rank 8 investigators
Slide 19: Phase 2a Trial Conclusion
LP-10 Phase 2a Trial Conclusion Trial Summary • LP-10 safety: • No Product related SAEs • Instillation procedure well tolerated by all subjects • LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake • Signal of efficacy and dose response • Hematuria improved, decreased cysto
Slide 20: Asset Pipeline and LP-310
Asset Pipeline and LP-310 LP-310: Liposomal tacrolimus for oral lichen planus Product Target Marketing Next Anticipated Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Approval Milestone Hemorrhagic Report top-line LP-10 Cystitis Data 4Q22 Oral Lichen IND submission LP-310 Planus 2Q23 Oral
Slide 21: LP-10 Development Team
LP-10 Development Team LP-10 is developed by an experienced team with complementary skillset and years of experience working together. Jonathan Kaufman, PhD Michael Chancellor, MD Michele Gruber Janet Okonski Chief Executive Officer Chief Medical Officer Director of Operations Director Clinical Oper
Slide 22: Liposomal Drug Delivery to Mucosal Surfaces
Liposomal Drug Delivery to Mucosal Surfaces 22
Slide 23: Lipella Pharmaceuticals Inc. contact details
Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412-894-1853 www.lipella.com 23
Lipella Pharmaceuticals — Investor Presentation (January 2023) on 6ix